Slide 1: Elevating the World's Wellbeing
Elevating the World’s Wellbeing January 2023 – March 2023 - Q1 2023 results presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q1 in short Business update Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q1 in short
Q1 in short Q1 Q2 Q3 Q4 4
Slide 5: Quarterly progress
Another quarter which achieves record revenue levels, exceeding medium term targets with a continued focus on profitability and cash generation 45% 36% 23% Adjusted EBITDA Q1 YTD 2023 Q1 YTD 2023 YTD increased to €0.9m revenue growth proforma revenue growth Quarterly progress - Our focus for the qua
Slide 6: Business updates
Business updates +b Physitrack
Slide 7: Our two business lines: Lifecare and Wellness
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Q@= Mental Wellbeing ‘Your Results rh nme hit eo End Dy AE— =| lt ! = ero = Lifecare Wellness Seamless and One platform, All ’ Efficient care areas of employee " So
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q1 Highlights: 7% growth in license numbers within Lifecare • Continued revenue growth supported by new users, revenue enhancers and price adjustments. 56,000 55,000 • Optimisation of technology and processes supporting margins in-line 54,000 with our long-term target
Slide 9: Wellness quarterly developments
Wellness quarterly developments Growth, Wellness segment Q1 Highlights: 1.6 1.4 • Continued impressive growth, powered by Champion Health UK and 1.2 Wellnow. 101% 1.0 0.8 • Notable wins with international mega-brands such as Coca-Cola 0.6 • Launch of new Champion Health London sales office and SDR/A
Slide 10: Revenue Evolution
Revenue Evolution 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 - Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Lifecare Wel lness Q1 Q2 Q3 Q4 10
Slide 11: Financial Results
Financial Results Q1 Q2 Q3 Q4 11
Slide 12: Q1 Financial Highlights
Q 1 2 Q1 Financial Highlights 3 month revenue 3 Month EBITDA 45% 171% €3.7m (Q1 2022: €2.6m) €0.7m (Q1 2022: €0.3m) Operating cashflow 12 month proforma 36% 31% revenue growth €0.7m (Q1 2022: €0.5m) 3 month adjusted EBITDA 3 month adjusted EBITDA margin 23% €0.9m (Q1 2022: €0.7m) 25% (Q1 2022: 29%)
Slide 13: Maintaining revenue growth
Q 1 2 Maintaining revenue growth In-line with medium term growth targets Lifecare technology Group Revenue revenue growth Wellness revenue growth 2.5 2.5 4.0 15% 36% 3.5 2.0 2.0 3.0 45% 2.5 1.5 1.5 2.0 1.0 1.0 1.5 101% 1.0 0.5 0.5 0.5 - - - Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4
Slide 14: EBITDA
Q 1 2 EBITDA Strong growth 1.0 0.9 23% €0.2M 0.8 0.7 0.6 €0.9M €0.7M €0.7M €0.5M 171% €'million 0.5 0.4 0.3 0.2 €0.2m ADJUSTED EBITDA ADJUSTED EBITDA Margin 0.1 Margin 29% 25% - 3 MONTHS 2022 EBITDA Adjusting items* 3 MONTHS 2022 3 MONTHS 2023 EBITDA Adjusting items* 3 MONTHS 2023 Adjuste d EBITDA A
Slide 15: Adjusted EBITDA by division
Q 1 2 Adjusted EBITDA 4.0 Adjusted EBITDA by division 3.5 1.2 49% 3.0 0.9 Q1 2023 4% 0.1 2.5 (0.3) 2.0 0.9 1.5 49% 1.0 0.9 1.0 Q1 2022 10% 0.1 23% (0.3) 0.5 0.9 0.7 - (0.4) (0.2) - 0.2 0.4 0.6 0.8 1.0 1.2 1.4 2022 ADJ EBITDA 2023 ADJ EBITDA Lifecare Wellness Group Q1 Q2 Q3 Q4 15 Q1 Q2 Q3 Q4
Slide 16: Cashflow
Q 1 2 Cashflow 4.0 Available liquidity €3.4m 3.0 €2.7m undrawn on facility 2.0 2.7 (0.3) (0.1) 1.0 0.9 (0.8) - 2.2 0.7 0.6 (1.6) - 1 Jan 2023 Opening Adjuste d EBITDA Working capital Interest expense Purchase of Deferred Adjusting items Drawdown of Fx 31 March 2023 Net cash intangibles consideration
Slide 17: Continued focus on Free-cash-flow
Q 1 2 Continued focus on Free-cash-flow - Q122 Q222 Q322 Q422 Q123 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment and finance costs 17 Q1 Q2 Q3 Q4
Slide 18: Balance Sheet
Q 1 2 Balance Sheet Strong liquidity position despite deferred consideration payments in Q1 31 March 2023 31 March 2022 Euros '000 Goodwill, intangibles and PPE 37,637 28,210 Cash and cash equivalents 726 8,549 Borrowings (3,018) - Trade and other receivables 3,002 2,251 Trade and other payables (2,
Slide 19: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 19
Slide 20: Large and expanding TAM
Large and expanding TAM Market size 2028 Business USD 1.103 Trillion 22% CAGR updates Market size 2022 USD 335 Billion Source: Arizton, Digital Health and Wellness Market - Global Outlook & Forecast 2023-2028 Q1 Q2 Q3 Q4 20
Slide 21: Market reflections – where things are heading
Market reflections – where things are heading TREND/DEVELOPMENT IMPACT ON PHYSITRACK Business Continued maturity, with consumers adopting digital health technologies Market penetration updates Revenue enhancement Leverage cost-cutting Increasing demand for cost reductions optimization Increasing dem
Slide 22: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes, through more personalized, data-driven care Positioned to capitalize on grow
Slide 23: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Growing market supported by 1. Market growth dynamics Physitrack aims to achieve annual organic sales underlying macro trends growth exceeding 30% in the medium t
Slide 24: Q&A
Q&A Q1 Q2 Q3 Q4 24